Home / Business and Economy / GSK Sees Profits Soar, But Future Growth May Slow
GSK Sees Profits Soar, But Future Growth May Slow
4 Feb
Summary
- GSK reported a 4% turnover increase to £32.7 billion in 2025.
- Specialty medicines, including HIV and asthma treatments, drove sales growth.
- The company anticipates a moderation in profit growth for 2026.
Pharmaceutical leader GSK has reported a substantial profit increase for 2025, with turnover climbing by 4% to £32.7 billion. This success was primarily fueled by strong demand for specialty medicines, including significant growth in respiratory, immunology, and inflammation treatments, alongside an 11% sales increase for HIV medication.
Under the leadership of new chief executive Luke Miels, GSK experienced robust trading. The company's core operating profits rose by 7% over the past year, accelerating to a 14% increase in the final quarter. Miels expressed confidence in GSK's position for future growth.
However, GSK has projected a moderation in its profit growth for 2026, expecting core operating profit growth between 7% and 9%. The company is also strategically avoiding the weight-loss drug market, preferring to focus on the downstream effects of obesity.
In recent developments, GSK has initiated an overhaul of its research and development division, leading to the elimination of approximately 350 jobs across the US and UK. Around 50 roles are being cut at the main UK R&D hub in Stevenage, Hertfordshire.
